Current treatments for chronic hand eczema (CHE) generally fall into two categories: those that combat inflammation but lead to unwanted side effects with long-term use, and those that soothe external symptoms without addressing underlying inflammation. This has created a significant gap in the CHE treatment landscape.
GlobalData highlights several emerging treatments that could fill this gap. Sanofi and Regeneron are testing their biologic Dupixent for CHE, while Asana BioSciences and Afecta Pharmaceuticals are exploring new molecules in this area. Leo Pharma has submitted its delgocitinib cream (Anzupgo) for FDA approval as a treatment for adults with moderate to severe CHE, marking a potential first for the U.S. market.
In a recent DELTA FORCE phase 3 trial, Anzupgo outperformed Toctino (alitretinoin), a treatment available outside the U.S., in reducing hand eczema severity index (HECSI) scores and improving health-related quality of life with fewer adverse events. This positions Anzupgo as a promising alternative to current CHE treatments, emphasizing the need for further research and clinical trials focused on safety and patient quality of life.
